U.S. patent application number 09/850965 was filed with the patent office on 2002-04-25 for novel compounds.
This patent application is currently assigned to Beecham Group p.1.c.. Invention is credited to Cawthorne, Michael Antony, Hindley, Richard Mark.
Application Number | 20020049240 09/850965 |
Document ID | / |
Family ID | 23409230 |
Filed Date | 2002-04-25 |
United States Patent
Application |
20020049240 |
Kind Code |
A1 |
Hindley, Richard Mark ; et
al. |
April 25, 2002 |
NOVEL COMPOUNDS
Abstract
Compounds of formula (I): 1 or a tautomeric form thereof, or a
pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate thereof, wherein: A.sup.1 represents a
substituted or unsubstituted aromatic heterocyclyl group; R.sup.1
represents a hydrocarbon atom, an alkyl group, an acyl grup, an
aralkyl group, wherein the aryl moiety may be substituted or
unsubstituted, or a substituted or unsubstituted aryl group;
R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3
together represent a bond; A.sup.2 represents a benzene ring having
a total up to five substituents; and n represents an integer in the
range of from 2 to 6; pharmaceutical compositions containing such
compounds and the use of such compounds and compositions in
medicine.
Inventors: |
Hindley, Richard Mark;
(Epsom, GB) ; Cawthorne, Michael Antony; (Epsom,
GB) |
Correspondence
Address: |
GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY - UW2220
P.O. BOX 1539
KING OF PRUSSIA
PA
19406-0939
|
Assignee: |
Beecham Group p.1.c.
|
Family ID: |
23409230 |
Appl. No.: |
09/850965 |
Filed: |
May 8, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09850965 |
May 8, 2001 |
|
|
|
08358327 |
Dec 19, 1994 |
|
|
|
Current U.S.
Class: |
514/369 ;
514/272 |
Current CPC
Class: |
C07D 277/20 20130101;
A61K 31/427 20130101; C07D 417/12 20130101; C07D 277/82 20130101;
C07D 277/42 20130101; A61K 31/426 20130101 |
Class at
Publication: |
514/369 ;
514/272 |
International
Class: |
A61K 031/426; A61K
031/427 |
Claims
1. A method for the treatment and/or prophylaxis of cardiovascular
diseases or eating disorders in a human or non-human mammal, which
comprises administering to said human or non-human mammal in need
thereof, an effective, non-toxic amount of a compound of formula
(I): 93or a tautomeric form thereof and/or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof, wherein: A.sup.1 represents a substituted or
unsubstituted aromatic heterocyclyl group; R.sup.1 represents a
hydrogen atom, an alkyl group, an acyl group, an aralkyl group,
wherein the aryl moiety may be substituted or unsubstituted, or a
substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each
represent hydrogen, or R.sup.2 and R.sup.3 together represent a
bond; A.sup.2 represents a benzene ring having in total up to five
substituents; and n represents an integer in the range of from 2 to
6.
2. A method according to claim 1, wherein A.sup.1 in the compound
of formula (I) represents a substituted or unsubstituted, single or
fused ring aromatic heterocyclyl group comprising up to 4 hetero
atoms in the ring selected from oxygen, sulphur or nitrogen.
3. A method according to claim 1, wherein A.sup.1 in the compound
of formula (I) represents a moiety of formula (a), (b) or (c):
94wherein: R.sup.4 and R.sup.5 each independently represents a
hydrogen atom, an alkyl group or a substituted or unsubstituted
aryl group or when R.sup.4 and R.sup.5 are each attached to a
carbon atom, then R and R.sup.5 together with the carbon atoms to
which they are attached form a benzene ring wherein each carbon
atom represented by R.sup.4 and R.sup.5 together may be substituted
or unsubstituted; and in the moiety of formula (a) X represents
oxygen or sulphur.
4. A method according to claim 3, wherein R.sup.4 and R.sup.5 in
(a), (b) or (c) each independently represent hydrogen, alkyl or a
substituted or unsubstituted phenyl group.
5. A method according to claim 3, wherein R.sup.4 and R.sup.5 in
(a), (b) or (c) together represent a moiety of formula (d):
95wherein R.sup.6 and R.sup.7 each independently represent
hydrogen, halogen, substituted or unsubstituted alkyl or
alkoxy.
6. A method according to claim 5, wherein R.sup.6 and R.sup.7in (d)
each represent hydrogen.
7. A method according to claim 1, wherein A.sup.2 in the compound
of formula (I) represents a moiety of formula (e): 96wherein
R.sup.8 and R.sup.9 each independently represent hydrogen, halogen,
substituted or unsubstituted alkyl or alkoxy.
8. A method according to claim 7, wherein R.sup.8 and R.sup.9 in
(e) each represent hydrogen.
9. A method according to claim 1, of formula (II): 97or a
tautomeric form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof,
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3 and n are as defined in
relation to formula (I) in claim 1 and R.sup.8 and R.sup.9 are as
defined in relation to formula (e) in claim 7.
10. A method according to claim 1, wherein n in the compound of
formula (I) represents an integer 2 or 3.
11. A method according to claim 1, wherein R.sup.1 in the compound
of formula (I) represents a methyl group.
12. A method according to claim 1 which comprises the
administration of a compound selected from the group consisting of:
5-(4-[2-(N-methyl-N-(2-be- nzothiazolyl)amino)ethoxy]
benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]
benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-(2-benzoxazolyl)a- mino)ethoxy]
benzyl)-2,4-thiazolidinedione; 5-(4-(2-(N-methyl-N-(2-benzoxa-
zolyl)amino)ethoxy] benzylidene)-2,4-thiazolidinedione;
5-(4-12-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidined-
ione; 5-(4-t2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]
benzylidene)-2,4-thiazolidinedione;
5-(4-(2-(N-methyl-N-[2-(4,5-dimethylt- hiazolyl)]amino)
ethoxy]benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
ethoxy]benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-(2-thiazol- yl)amino)ethoxy]benzyl)
-2,4-thiazolidinedione; 5-(4-[2-(N-methyl-N-(2-thi-
azolyl)amino)ethoxy] benzylidene)-2,4-thiazolidinedione;
5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)
ethoxy)benzyl]-2,4-thia- zolidinedione;
5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)
ethoxy]benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4-phen-
yl-5-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]
amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(- 4-methyl-5-phenylthiazolyl)]
amino)ethoxy]benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]
amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
5-(4-(2-(N-methyl-N-[2-(- 4-methylthiazolyl)]
amino)ethoxy]benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)
ethoxy]benzylidene)-2,4- -thiazolidinedione;
5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl))amino) ethoxy)
benzyl]-2,4-thiazolidinedione; 5-(4-[2-(N-methyl-N-[2-(5-phenylox-
azolyl)]amino) ethoxy]benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)
ethoxy]benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-methyl-N-[2-(4,5-dimethy-
loxazolyl)]amino)-ethoxy]benzylidene)-2,4-thiazolidinedione;
5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidinedione;
5-[4-(2-(2-pyrimidinylamino)ethoxy)benzylidene]-2,4-thiazolidinedione;
5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)
-2,4-thiazolidinedione;
5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethox- y)
benzylidene)-2,4-thiazolidinedione;
5-(4-(2-(N-(2-benzothiazolyl)-N-ben- zylamino)ethoxy)
benzyl)-2,4-thiazolidinedione; 5-(4-(3-(N-methyl-N-(2-ben-
zoxazolyl)amino)propoxy] benzyl)-2,4-thiazolidinedione;
5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzylidene)-2,4-thiazo-
lidinedione;
5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiaz-
olidinedione;
5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-
-thiazolidinedione;
5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzy-
lidene)-2,4-thiazolidinedione;
5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)b-
utoxy]-benzyl)-2,4-thiazolidinedione;
5-(4-[2-(N-(2-benzoxazolyl)amino)eth-
oxy]benzylidene)-2,4-thiazolidinedione;
5-(4-[2-(N-(2-benzoxazolyl)amino)e- thoxy]benzyl)-2,
4-thiazolidinedione; and 5-(4-[2-(N-isopropyl-N-(2-benzox-
azolyl)amino)ethoxy] benzyl)-2,4-thiazolidinedione; or a tautomeric
form thereof and/or a pharmaceutically acceptable salt thereof
and/or a pharmaceutically acceptable solvate thereof.
Description
[0001] This invention relates to certain substituted
thiazolidinedione derivatives, to a process for preparing such
compounds, to pharmaceutical compositions containing such compounds
and to the use of such compounds and compositions in medicine.
[0002] European Patent Applications, Publication Numbers 0008203,
0139421, 0155845, 0177353, 0193256, 0207581 and 0208420 relate to
thiazolidinedione derivatives which are disclosed as having
hypoglycaemic and hypolipidaemic activity. Chem. Pharm. Bull 30
(10) 3580-3600 also relates to certain thiazolidinedione
derivatives having hypoglycaemic and hypolipidaemic activities.
[0003] It has now surprisingly been discovered that certain novel
substituted-thiazolidinedione derivatives show improved
blood-glucose lowering activity and are therefore of potential use
in the treatment and/or prophylaxis of hyperglycaemia and are of
particular use in the treatment of Type II diabetes. These
compounds are also indicated to be of potential use for the
treatment and/or prophylaxis of other diseases including
hyperlipidaemia and hypertension.
[0004] They are also indicated to be of use in the treatment and/or
prophylaxis of cardiovascular disease, especially atherosclerosis.
In addition these compounds are considered to be useful for
treating certain eating disorders, in particular the regulation of
appetite and food intake in subjects suffering from disorders
associated with under-eating ,such as anorexia nervosa, and
disorders associated with over-eating, such as obesity and anorexia
bulimia.
[0005] Accordingly, the present invention provides a compound of
formula (I): 2
[0006] or a tautomeric form thereof and/or a pharmaceutically
acceptable salt thereof, and/or a pharmaceutically acceptable
solvate thereof, wherein:
[0007] A.sup.1 represents a substituted or unsubstituted aromatic
heterocyclyl group;
[0008] R.sup.1 represents a hydrogen atom, an alkyl group, an acyl
group, an aralkyl group, wherein the aryl moiety may be substituted
or unsubstituted, or a substituted or unsubstituted aryl group;
[0009] R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and
R.sup.3 together represent a bond;
[0010] A.sup.2 represents a benzene ring having in total up to five
substituents; and
[0011] n represents an integer in the range of from 2 to 6.
[0012] Suitable aromatic heterocyclyl groups include substituted or
unsubstituted, single or fused ring aromatic heterocyclyl groups
comprising up to 4 hetero atoms in each ring selected from oxygen,
sulphur or nitrogen.
[0013] Favoured aromatic heterocyclyl groups include substituted or
unsubstituted single ring aromatic heterocyclyl groups having 4 to
7 ring atoms, preferably 5 or 6 ring atoms.
[0014] In particular, the aromatic heterocyclyl group comprises 1,
2 or 3 heteroatoms, especially 1 or 2, selected from oxygen,
sulphur or nitrogen.
[0015] Suitable values for A.sup.1 when it represents a 5-membered
aromatic heterocyclyl group include thiazolyl and oxazolyl,
especially oxazolyl.
[0016] Suitable values for A.sup.1 when it represents a 6-membered
aromatic heterocyclyl group include pyridyl or pyrimidinyl.
[0017] Suitably R.sup.2 and R.sup.3 each represent hydrogen.
[0018] Preferably, A.sup.1 represents a moiety of formula (a), (b)
or (c): 3
[0019] wherein: R.sup.4 and R.sup.5 each independently represents a
hydrogen atom, an alkyl group or a substituted or unsubstituted
aryl group or when R.sup.4 and R.sup.5 are each attached to
adjacent carbon atoms, then R.sup.4 and R.sup.5 together with the
carbon atoms to which they are attached form a benzene ring wherein
each carbon atom represented by R.sup.4 and R.sup.5 together may be
substituted or unsubstituted; and in the moiety of formula (a)
[0020] x represents oxygen or sulphur.
[0021] Aptly, A.sup.1 represents a moiety of the abovedefined
formula (a).
[0022] Aptly, A.sup.1 represents a moiety of the abovedefined
formula (b).
[0023] Aptly, A.sup.1 represents a moiety of the abovedefined
formula (c)
[0024] In one favoured aspect R.sup.4 and R.sup.5 together
represent a moiety of formula (d): 4
[0025] wherein R.sup.6 and R.sup.7 each independently represent
hydrogen, halogen, substituted or unsubstituted alkyl or
alkoxy.
[0026] Suitably, R.sup.6 and R.sup.7 each independently represent
hydrogen, halogen, alkyl or alkoxy.
[0027] Favourably, R.sup.6 represents hydrogen. Favourably,
R.sup.7represents hydrogen.
[0028] Preferably, R.sup.6 and R.sup.7 both represent hydrogen.
[0029] In a further favoured aspect R.sup.4 and R.sup.5 each
independently represent hydrogen, alkyl or a substituted or
unsubstituted phenyl group and more favourably, R.sup.4 and R.sup.5
each independently represent hydrogen, alkyl or phenyl.
[0030] Preferably, for the moiety of formula (a), R.sup.4 and
R.sup.5 together represent the moiety of formula (d).
[0031] Preferably, for the moieties of formula (b) or (c), R.sup.4
and R.sup.5 both represent hydrogen.
[0032] It will be appreciated that the five substituents of A.sup.2
include three optional substituents. Suitable optional substituents
for the moiety A.sup.2 include halogen, substituted or
unsubstituted alkyl or alkoxy.
[0033] Favourably, A.sup.2 represents a moiety of formula (e):
5
[0034] wherein R.sup.8 and R.sup.9 each independently represent
hydrogen, halogen, substituted or unsubstituted alkyl or
alkoxy.
[0035] Suitably, R.sup.8 and R.sup.9 each independently represent
hydrogen, halogen, alkyl or alkoxy. Preferably, R.sup.8 and R.sup.9
each represent hydrogen.
[0036] Favourably, X represents oxygen. Favourably, x represents
sulphur.
[0037] In one preferred aspect the present invention provides a
class of compounds, which fall wholly within the scope of formula
(I), of formula (II): 6
[0038] or a tautomeric form thereof, and/or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof, wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, and n
are as defined in relation to formula (I) and R.sup.8 and R.sup.9
are as defined in relation to formula (e).
[0039] Suitably, n represents an integer 2, 3 or 4, notably 2 or 3
and especially 2.
[0040] Suitably, R.sup.1 represents hydrogen, alkyl, acyl,
especially acetyl, or benzyl.
[0041] When R.sup.1 represents an alkyl group, examples of such
alkyl groups include methyl and isopropyl. Preferably, R.sup.1
represents a methyl group.
[0042] As indicated above a compound of formula (I) may exist in
one of several tautomeric forms, all of which are encompassed by
the present invention. It will be appreciated that the present
invention encompasses all of the isomeric forms of the compounds of
formula (I) and the pharmaceutically acceptable salts thereof,
including any stereoisomeric forms thereof, whether as individual
isomers or as mixtures of isomers.
[0043] Suitable substituents for any heterocyclyl group include up
to 4 substituents selected from the group consisting of: alkyl,
alkoxy, aryl and halogen or any two substituents on adjacent carbon
atoms, together with the carbon atoms to which they are attached,
may form an aryl group, preferably a benzene ring, and wherein the
carbon atoms of the aryl group represented by the said two
substituents may themselves be substituted or unsubstituted.
[0044] When used herein the term `aryl` includes phenyl and
naphthyl optionally substituted with up to five, preferably up to
three, groups selected from halogen, alkyl, phenyl, alkoxy,
haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl,
alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
[0045] When used herein the term `halogen` refers to fluorine,
chlorine, bromine and iodine; preferably chlorine.
[0046] When used herein the terms `alkyl` and `alkoxy` relate to
groups having straight or branched carbon chains, containing up to
12 carbon atoms.
[0047] When used herein the term `acyl` includes alkylcarbonyl
groups.
[0048] Suitable alkyl groups are C.sub.1-12 alkyl groups,
especially C.sub.1-6 alkyl groups e.g. methyl, ethyl, n-propyl,
iso-propyl, n-butyl, isobutyl or tert-butyl groups.
[0049] Suitable substituents for any alkyl group include those
indicated above in relation to the term `aryl`.
[0050] Suitable pharmaceutically acceptable salts include salts of
the thiazolidinedione moiety, and, where appropriate, salts of
carboxy groups.
[0051] Suitable pharmaceutically acceptable salts of the
thiazolidinedione moiety include metal salts especially alkali
metal salts such as the lithium, sodium and potassium salts.
[0052] Suitable pharmaceutically acceptable salts of carboxy groups
include metal salts, such as for example aluminium, alkali metal
salts such as sodium or potassium, alkaline earth metal salts such
as calcium or magnesium and ammonium or substituted ammonium salts,
for example those with lower alkylamines such as triethylamine,
hydroxy alkylamines such as 2-hydroxyethylamine,
bis-(2-hydroxyethyl)-amine or (2-hydroxyethyl)-amine,
cycloalkylamines such as bicyclohexylamine, or with procaine,
dibenzylpiperidine, N-benzyl-P-phenethylamine, dehydroabietylamine,
N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases
of the pyridine type such as pyridine, collidine or quinoline.
[0053] Suitable pharmaceutically acceptable solvates include
hydrates.
[0054] In a further aspect the present invention also provides a
process for the preparation of a compound of formula (I), or a
tautomeric form thereof, and/or a pharmaceutically acceptable salt
thereof, and/or a pharmaceutically acceptable solvate thereof,
which process comprises reacting a compound of formula (III): 7
[0055] wherein R.sup.2, R.sup.3 and A.sup.2 are as defined in
relation to formula (I), and R.sup.a is a moiety convertible to a
moiety of formula (f): 8
[0056] wherein R.sup.1, A.sup.1, and n are as defined in relation
to formula (I), with an appropriate reagent capable of converting
R.sup.a to the said moiety (f) and thereafter, if required,
carrying out one or more of the following optional steps:
[0057] (i) converting a compound of formula (I) to a further
compound of formula (I);
[0058] (ii) preparing a pharmaceutically acceptable salt of the
compound of formula (I) and/or a pharmaceutically acceptable
solvate thereof.
[0059] Suitably, R.sup.a represents
R.sup.1HN--(CH.sub.2).sub.n--O-wherein R.sup.1 and n are as defined
in relation to formula (I).
[0060] Suitably, when R.sup.a is R.sup.1HN--(CH.sub.2)n--O--, an
appropriate reagent capable of converting R.sup.a to a moiety (f)
is a compound of formula (IV):
A.sup.l--R.sup.x (IV)
[0061] wherein A.sup.1 is as defined in relation to formula (I) and
R.sup.x represents a leaving group.
[0062] A suitable leaving group Rx includes a halogen atom,
preferably a chlorine or bromine atom, or a thioalkyl group for
example a thiomethyl group.
[0063] The reaction between the compound of formula (III) and the
appropriate reagent may be carried out under conditions suitable to
the particular compound of formula (III) and the reagent chosen;
thus for example the abovementioned reaction between a compound of
formula (III) wherein R.sup.a represents
R.sup.1HN--(CH.sub.2).sub.n--O-- and the compound of formula (IV),
may be carried out in any suitable solvent, for example
tetrahydrofuran, at a temperature in the range of between 0.degree.
and 60.degree. C.
[0064] A compound of formula (III) may be prepared from a compound
of formula (V): 9
[0065] wherein A.sup.2 is as defined in relation to the compound of
formula (I) and R.sup.b is a moiety R.sup.a, or a moiety
convertible to a moiety R.sup.a; by reaction of the compound of
formula (V) with 2,4-thiazolidinedione; and thereafter if required
carrying out one or more of the following optional steps:
[0066] (i) reducing a compound of formula (III) wherein R.sup.2 and
R.sup.3 together represent a bond, into a compound of formula (III)
wherein R.sup.2 and R.sup.3 each represent hydrogen;
[0067] (ii) converting a moiety R.sup.b to a moiety R.sup.a.
[0068] The reaction between the compound of formula (V) and
2,4-thiazolidinedione will of course be carried out under
conditions suitable to the nature of the compound is of formula
(V), in general the reaction being carried out in a solvent such as
toluene, suitably at an elevated temperature such as the reflux
temperature of the solvent and preferably in the presence of a
suitable catalyst such as piperidinium acetate or benzoate.
Favourably, in the reaction between the compound of formula (V) and
2,4-thiazolidinedione, the water produced in the reaction is
removed from the reaction mixture, for example by means of a Dean
and Stark apparatus.
[0069] When R.sup.a represents R.sup.1HN--(CH.sub.2).sub.n--O--, a
suitable value for R.sup.b is a hydroxyl group.
[0070] The moiety R.sup.b may be converted to the moiety R.sup.a by
any suitable means, for example when R.sup.b represents a hydroxyl
group and R.sup.a represents R.sup.1HN(CH.sub.2).sub.n--O-- the
appropriate conversion may be carried out by coupling a compound of
formula (VA): 10
[0071] wherein R.sup.2, R.sup.3 and A.sup.2 are as defined in
relation to formula (I) and R.sup.Z is hydrogen or a nitrogen
protecting group, with a compound of formula (VI):
R.sup.1NR.sup.X(CH.sub.2).sub.n--OH (VI)
[0072] wherein R.sup.1 and n are as defined in relation to formula
(I) and R.sup.x is hydrogen or a nitrogen protecting group, in the
presence of a suitable coupling agent; and thereafter, if required,
carrying out one or more of the following optional steps:
[0073] (i) reducing a compound of formula (III) wherein R.sup.2 and
R.sup.3 together represent a bond, to a compound of formula (III)
wherein R.sup.2 and R.sup.3 each represent hydrogen;
[0074] (ii) removing any nitrogen protecting group.
[0075] A suitable coupling agent for the coupling reaction between
the compound of formula (VA) and (VI) is provided by
diethylazodicarboxylate and triphenylphosphine. The coupling
reaction may be carried out in any suitable solvent at a low to
medium temperature, for example in tetrahydrofuran at a temperature
in the range of between 0.degree. and 60.degree. C.
[0076] One example of the preparation of a compound of formula (VA)
is that wherein a compound falling within formula
[0077] (v) of particular formula (VII): 11
[0078] wherein A.sup.2 is as defined in relation to formula (I),
and R.sup.11 represents a hydroxyl group or a protected hydroxyl
group, is reacted with 2,4-thiazolidinedione; and thereafter if
required removing any protecting group.
[0079] Preferably, R.sup.11 represents a benzyloxy group.
[0080] Suitable conditions for the reaction between a compound of
formula (VII) and 2,4-thiazolidinedione are those defined above in
relation to the reaction between the compounds of formula (V) and
2,4-thiazolidinedione.
[0081] The compounds of formula (IV), (VI) and (VII) are either
known compounds or are prepared using methods analogous to those
used to prepare known compounds.
[0082] Suitable protecting groups in any of the abovementioned
reactions are those used conventionally in the art. Thus, for
example, a suitable nitrogen protecting group is a benzyl group or
a benzyloxycarbonyl group and a suitable hydroxyl protecting group
is a benzyl group.
[0083] The methods of formation and removal of such protecting
groups are those conventional methods appropriate to the molecule
being protected. Thus for example when
[0084] R.sup.11 represents a benzyloxy group such group may be
prepared by treatment of the appropriate compound of formula (VII),
wherein R.sup.11 is a hydroxyl group with a benzyl halide, such as
benzyl bromide, and thereafter when required the benzyl group may
be conveniently removed using a mild ether cleavage reagent such as
trimethylsilyliodide.
[0085] A compound of formula (I), or a tautomeric form thereof,
and/or a pharmaceutically acceptable salt thereof and/or a
pharmaceutically acceptable solvate thereof, may also be prepared
by reacting a compound of formula (VIII): 12
[0086] wherein R.sup.1, A.sup.1, A.sup.2, and n are as defined in
relation to formula (I) with 2,4-thiazolidinedione; and thereafter
if required carrying out one or more of the following optional
steps:
[0087] (i) converting a compound of formula (I) into a further
compound of formula (I);
[0088] (ii) preparing a pharmaceutically acceptable salt of a
compound of formula (I) and/or a pharmaceutically acceptable
solvate thereof.
[0089] The reaction between a compound of formula (VIII) and
2,4-thiazolidinedione may suitably be carried out under analogous
conditions to those used in the reaction between a compound of
formula (V) and 2,4-thiazolidinedione.
[0090] A compound of formula (VIII) may be prepared by reacting a
compound of formula (IX): 13
[0091] wherein A.sup.2 is as defined in relation to formula (I) and
R.sup.a is as defined in relation to formula (III), with an
appropriate reagent capable of converting R.sup.a to the above
defined moiety (f).
[0092] Suitable values for R.sup.a include those described above in
relation to the compound of formula (III). Thus R.sup.a may
represent R.sup.1HN--(CH.sub.2).sub.n--O--, as defined above, and
hence the appropriate compound of formula (IX) may be reacted with
a reagent of the abovedefined formula (IV) to provide the required
compound of formula (VIII).
[0093] Suitable reaction conditions for the reaction of the
compound of formula (IX) and the appropriate reagent may include
those described above in relation to the preparation of compound
(III) with the said appropriate reagent.
[0094] Preferably, for the compound of formula (IX), R.sup.a
represents a leaving group, especially a fluorine atom. When
R.sup.a represents a leaving group, preferably a fluorine atom, a
particularly appropriate reagent is a compound of formula (X):
14
[0095] wherein R.sup.1, A.sup.1, and n are as defined in relation
to formula (I).
[0096] The reaction between the compounds of formulae (IX) and (X)
may be carried out under any suitable conditions, for example in a
solvent such as dimethylformamide or dimethylsulphoxide at an
elevated temperature for example in the range of between
100.degree. to 150.degree. C., suitably in the presence of a base
such as sodium hydride or potassium carbonate.
[0097] In the compound of formula (IX) R.sup.a may also represent a
hydroxyl group.
[0098] When R.sup.a, in the compound of formula (IX), represents a
hydroxyl group a particularly appropriate reagent is a compound of
the abovedefined formula (X) or a compound of formula (XA): 15
[0099] wherein A.sup.1, R.sup.1 and n are as defined in relation to
formula (X) and R.sup.Y represents a tosylate or mesylate
group.
[0100] The reaction between the compound of formula (IX) wherein
R.sup.a is a hydroxyl group and the reagent of the abovedefined
formula (X) may suitably be carried out in an aprotic solvent, such
as tetrahydrofuran, at low to medium temperature, for example at
ambient temperature, and preferably in the presence of a coupling
agent such as that provided by triphenylphosphine and
diethylazodicarboxylate.
[0101] The reaction between the compound of formula (IX), wherein
R.sup.a is a hydroxyl group, and the reagent of the abovedefined
formula (XA) may be carried out in an aprotic solvent, such as
dimethylformamide, at a low to elevated temperature, for example in
the range of from 50.degree. C. to 120.degree. C. and preferably in
the presence of a base, such as sodium hydride.
[0102] The compound of formula (XA) may be prepared from the
corresponding compound of formula (X) by reaction with either a
tosyl halide or a mesyl halide in a solvent such as pyridine.
[0103] The compounds of formula (IX) are known compounds or
compounds prepared by methods analogous to those used to prepare
known compounds, for example 4-fluorobenzaldehyde and
4-hydroxybenzaldehyde are known commercially available
compounds.
[0104] The reagent of formula (X) may be prepared by reacting a
compound of the hereinabove defined formula (IV), with a compound
of the hereinbefore defined formula (VI) and thereafter if required
removing any nitrogen protecting group using the appropriate
conventional conditions.
[0105] The reaction between the compounds of formula (IV) and (VI)
may be carried out under any suitable conditions, such as in
solvent, for example in an aprotic solvent such as tetrahydrofuran,
at a low to medium temperature, for example a temperature in the
range of from 0.degree. to 60.degree. C.
[0106] Favourably when R.sup.1 represents hydrogen the reaction is
carried out using the compound of formula (VI) as a solvent at a
low to elevated temperature, suitably an elevated temperature such
as in the range of between 100.degree. and 170.degree. C.
[0107] The abovementioned conversion of a compound of formula (I)
into a further compound of formula (I) includes the following
conversions:
[0108] (a) reducing a compound of formula (I) wherein R.sup.2 and
R.sup.3 together represent a bond, to a compound of formula (I)
wherein R.sup.2 and R.sup.3 each represent hydrogen; and
[0109] (b) converting one group R.sup.1 into another group
R.sup.1.
[0110] The conversion of a compound of formula (I) to a further
compound of formula (I) may be carried out by using any appropriate
conventional procedure.
[0111] A suitable reduction method for the abovementioned
conversion (a) includes catalytic reduction or the use of a
metal/solvent reducing system.
[0112] Suitable catalysts for use in the catalytic reduction are
palladium on carbon catalysts, preferably a 10% palladium on
charcoal catalyst; the reduction being carried out in a solvent,
for example dioxan, suitably at ambient temperature.
[0113] Suitable metal/solvent reducing systems include magnesium in
methanol.
[0114] The abovementioned reduction of a compound of formula (III)
wherein R.sup.2 and R.sup.3 together represent a bond to a compound
of formula (III) wherein R.sup.2 and R.sup.3 each represent
hydrogen, may be carried out under analogous conditions to those
referred to above in conversion (a) of the compound of formula
(I).
[0115] In the abovementioned conversion (b), suitable conversions
of one group R.sup.1 into another group R.sup.1 includes converting
a group R.sup.1 which represents hydrogen into a group R.sup.1
which represents an acyl group.
[0116] The conversion of a compound of formula (I) wherein R.sup.1
represents hydrogen into a compound of formula (I) wherein R.sup.1
represents acyl may be carried out using any appropriate
conventional acylation procedure, such as by treating an
appropriately protected compound of formula (I) with an acylating
agent. For example acetic anhydride may be used to prepare the
compound of formula (I) wherein R.sup.1 is acetyl.
[0117] It will be appreciated that in the abovementioned
conversions (a) and (b), any reactive group in the compound of
formula (I) would be protected, according to conventional chemical
practice, where necessary.
[0118] Where appropriate the isomeric forms of the compounds of
formula (I) and the pharmaceutically acceptable salts thereof may
be prepared as individual isomers using conventional chemical
procedures.
[0119] As mentioned above the compounds of the invention are
indicated as having useful therapeutic properties:
[0120] The present invention accordingly provides a compound of
formula (I), or a tautomeric form thereof and/or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof, for use as an active therapeutic substance.
[0121] Thus the present invention provides a compound of formula
(I), or a tautomeric form thereof and/or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof, for use in the treatment of and/or prophylaxis of
hyperglycaemia, hyperlipidaemia and hypertension.
[0122] A compound of formula (I), or a tautomeric form thereof
and/or a pharmaceutically acceptable salt thereof and/or a
pharmaceutically acceptable solvate thereof, may be administered
per se or, preferably, as a pharmaceutical composition also
comprising a pharmaceutically acceptable carrier.
[0123] Accordingly, the present invention also provides a
pharmaceutical composition comprising a compound of the general
formula (I), or a tautomeric form thereof, or a pharmaceutically
acceptable salt thereof, or a pharmaceutically acceptable solvate
thereof, and a pharmaceutically acceptable carrier therefor.
[0124] As used herein the term `pharmaceutically acceptable`
embraces compounds, compositions and ingredients for both human and
veterinary use: for example the term `pharmaceutically acceptable
salt` embraces a veterinarily acceptable salt.
[0125] The composition may, if desired, be in the form of a pack
accompanied by written or printed instructions for use.
[0126] Usually the pharmaceutical compositions of the present
invention will be adapted for oral administration, although
compositions for administration by other routes, such as by
injection and percutaneous absorption are also envisaged.
[0127] Particularly suitable compositions for oral administration
are unit dosage forms such as tablets and capsules. Other fixed
unit dosage forms, such as powders presented in sachets, may also
be used.
[0128] In accordance with conventional pharmaceutical practice the
carrier may comprise a diluent, filler, disintegrant, wetting
agent, lubricant, colourant, flavourant or other conventional
adjuvant.
[0129] Typical carriers include, for example, microcrystalline
cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone,
polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl
sulphate or sucrose.
[0130] Most suitably the composition will be formulated in unit
dose form. Such unit dose will normally contain an amount of the
active ingredient in the range of from 0.1 to 1000 mg, more usually
0.1 to 500 mg, and more especially 0.1 to 250 mg.
[0131] The present invention further provides a method for the
treatment and/or prophylaxis of hyperglycaemia or hyperlipidaemia
in a human or non-human mammal which comprises administering an
effective, non-toxic, amount of a compound of the general formula
(I), or a tautomeric form thereof and/or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof to a hyperglycaemic human or non-human mammal in
need thereof.
[0132] The present invention further provides a method for the
treatment of cardiovascular disease, especially atherosclerosis, in
a human or non-human mammal, which comprises administering an
effective, non-toxic, amount of a compound of formula (I), or a
tautomeric form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof, to a
human or non-human mammal in need thereof.
[0133] The present invention also provides a method for the
treatment of certain eating disorders, in particular the regulation
of appetite and food intake in disorders associated with
under-eating, such as anorexia nervosa, and disorders associated
with over-eating, such as obesity and anorexia bulimia, in a human
or non-human mammal, which comprises administering an effective,
non-toxic, amount of a compound of formula (I), or a tautomeric
form thereof and/or a pharmaceutically acceptable salt thereof
and/or a pharmaceutically acceptable solvate thereof, to a human or
non-human mammal in need thereof.
[0134] Conveniently, the active ingredient may be administered as a
pharmaceutical composition hereinbefore defined, and this forms a
particular aspect of the present invention.
[0135] In the above mentioned treatments the compound of the
general formula (I), or a tautomeric form thereof and/or a
pharmaceutically acceptable salt thereof and/or a pharmaceutically
acceptable solvate thereof, may be taken in doses, such as those
described above, one to six times a day in a manner such that the
total daily dose for a 70 kg adult will generally be in the range
of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.
[0136] In the treatment and/or prophylaxis of hyperglycaemic
non-human mammals, especially dogs, the active ingredient may be
adminstered by mouth, usually once or twice a day and in an amount
in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1
mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the
treatment and/or prophylaxis of hyperlipidaemia in non-human
mammals.
[0137] The following Procedures and Examples illustrate the
invention but do not limit it in any way.
[0138] Preparation 1
[0139]
4-[2-(N-Methyl-N-(2-benzothiazolyl)amino)ethoxy]-benzaldehyde
16
[0140] A mixture of 4-fluorobenzaldehyde (1.5 g) and
2-[N-methyl-N-(2-benzothiazolyl)amino]ethanol (2.4 g) in dimethyl
sulphoxide (50 ml) containing anhydrous potassium carbonate (2 g)
was stirred at 100.degree. C. for 24 hours. The mixture was cooled
to room temperature and added to water (300 ml). The aqueous
solution was extracted with diethyl ether (2.times.300 ml). The
organic extracts were washed with brine (1.times.300 ml), dried
(MgSO.sub.4), filtered and evaporated to dryness. The title
compound was obtained as a waxy solid following chromatography on
silica-gel in 1% methanol in dichloromethane.
[0141] .sup.1H NMR .delta. (CDCl.sub.3)
[0142] 3.2 (3H, s); 3.8 (2H, t); 4.2 (2H, t); 6.8-7.8 (8H,
complex); 9.8 (1H, s).
[0143] Preparation 2
[0144] 2- [N-Methyl-N-(2-benzothiazolyl)amino]ethanol 17
[0145] A mixture of 2-chlorobenzothiazole (8.5 g) and
2-methylaminoethanol (20ml) was heated at 120.degree. C. under
pressure in a sealed, glass lined, stainless steel reaction vessel
for 18 hours. After cooling, the oil was added to water (100 ml),
extracted with dichloromethane (2.times.100 ml), the organic
extracts were dried (MgSO.sub.4), filtered and evaporated to
dryness. Chromatography of the residual oil on silica-gel in 21/2%
methanol in dichloromethane gave the title compound which was used
in Preparation 1 without further purification.
[0146] .sup.1H NMR .delta. (CDCl.sub.3)
[0147] 3.15 (3H, s); 3.4-4.0 (4H, m); 4.7 (1H, broad s, exchanges
with D.sub.2O); 6.8-7.6 (4H, complex).
[0148] Preparation 3
[0149] 4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]-benzaldehyde
18
[0150] To a solution of 2-[N-methyl-N-(2-benzoxazolyl)
amino]ethanol (9.6 g), triphenylphosphine (13.1 g) and
4-hydroxybenzaldehyde (6.1 g) in dry tetrahydrofuran (150 ml) was
added dropwise a solution of diethyl azodicarboxylate (9.0 g) in
dry tetrahydrofuran (30 ml), under a blanket of nitrogen with
stirring at room temperature. The solution was stirred overnight at
room temperature following which the solvent was removed under
reduced pressure. The residue was dissolved in diethyl ether (300
ml), filtered and the ether solution was washed with dilute sodium
hydroxide solution (200 ml), saturated brine (200 ml), dried
(MgSO.sub.4), filtered and the solvent evaporated. The title
compound (mp 97.degree.-98.degree. C.) was obtained after
chromatography on silica-gel, eluting with dichloromethane.
[0151] .sup.1H NMR .delta. (CDCl.sub.3)
[0152] 3.30 (3H, s); 3.85 (2H, t); 4.30 (2H, t) 6.80-7.85 (8H,
complex); 9.85 (1H, s).
[0153] Preparation 4
[0154] 2-[N-Methyl-N-(2-benzoxazolyl)amino]ethanol 19
[0155] A solution of 2-chlorobenzoxazole (15.4 g) in dry
tetrahydrofuran (50 ml) was added dropwise to an ice cooled
solution of 2-methylaminoethanol (15.0 g) in dry tetrahydrofuran
(10 ml) with stirring and protection from atmospheric moisture. The
mixture was stirred at 0.degree. C. for 1 hour, allowed to warm to
room temperature and stirred for a further 2 hours. The solvent was
removed under reduced pressure, the product was dissolved in ethyl
acetate (200 ml) and washed with brine (2.times.150 ml). The
organic layer was dried (MgSO.sub.4), filtered and the solvent
evaporated. Chromatography ok the residue on silica-gel in
dichloromethane gave the title compound (mp 62.degree.-3.degree.
C.) which was used in Preparation 3 without further
purification.
[0156] .sup.1H NMR .delta. (CDCl.sub.3)
[0157] 3.12 (3H S); 3.4-4.0 (4H, m); 4.7 (1H, s, exchanges with
D.sub.20); 6.8-7.4 (4H, complex).
[0158] Preparation 5
[0159] 4-[2-(N-Methyl-N-(2-pyrimidinyl)amino)ethoxy]-benzaldehyde
20
[0160] A mixture of 4-fluorobenzaldehyde (12 ml) and
2-[N-methyl-N-(2-pyrimidinyl)amino]ethanol (10.05 g) in dry
dimethyl sulphoxide (50 ml) containing anhydrous potassium
carbonate (15 g) was stirred at 120.degree. C. for 6 hours. The
mixture was cooled to room temperature and added to water (200 ml).
The aqueous solution was extracted with ethyl acetate (2.times.300
ml), the organic extracts washed with brine, dried (MgSO.sub.4) and
evaporated. The title compound was obtained as an oil following
chromatography on silica-gel in 2% methanol in dichloromethane.
[0161] .sup.1H NMR .delta. (CDCl.sub.3)
[0162] 3.3 (3H, s); 3.8-4.4 (4H, complex); 6.5 (1H, t); 7.0 (2H,
d); 7.8 (2H, d); 8.3 (2H, d); 9.9 (1H, s).
[0163] Preparation 6
[0164] 2-[N-Methyl-N-(2-pyrimidinyl)amino]ethanol 21
[0165] A mixture of 2-chloropyrimidine (10 g) and
2-methylaminoethanol in dry tetrahydrofuran (100 ml) was boiled
under reflux for 3 hours. The solution was cooled, water (200 ml)
was added, the mixture extracted with dichloromethane, the organic
extracts were dried (MgSO.sub.4), filtered and evaporated to
dryness. The residual oil was used in Preparation 5 without further
purification.
[0166] .sup.1H NMR .delta. (CDCl.sub.3)
[0167] 3.2 (3H, s); 3.5-3.9 (4H, m); 4.6 (1H, s, exchanges with
D.sub.2O); 6.4 (1H, t); 8.2 (2H, d).
[0168] Preparation 7
[0169] 2-[N-Methyl-N-(2-[4,5-dimethylthiazolyl])amino]ethanol
22
[0170] A solution of 2-chloro-4,5-dimethylthiazole (13.2 g) and
2-methylaminoethanol (40 ml) in pyridine (100 ml) was boiled under
reflux for 20 hours. After cooling, the oil was added to water (300
ml) and extracted with ethyl acetate (3.times.200 ml). The organic
extracts were washed with brine (2.times.200 ml), dried
(MgSO.sub.4), filtered and evaporated to dryness to leave the title
compound which was used in Preparation 14 without further
purification.
[0171] .sup.1H NMR .delta. (CDCl.sub.3)
[0172] 2.15 (3H, s); 2.20 (3H, s); 3.1 (3H, s); 3.4-3.9 (4H, m);
5.25 (1H, broad s, exchanges with D.sub.2O).
[0173] Preparation 8
[0174] 2-[N-Methyl-N-(2-thiazolyl)amino]ethanol 23
[0175] The title compound was prepared as an oil from
2-bromothiazole (15 g) and 2-methylaminoethanol (45 ml) by an
analogous procedure to that described in Preparation 7
[0176] .sup.1H NMR .delta. (CDCl.sub.3)
[0177] 3.1 (3H, s); 3.4-3.9 (4H, m); 4.8 (1H, broad s, exchanges
with D.sub.20); 6.4 (1H, d); 7.0 (1H, d).
[0178] Preparation 9
[0179] 2-[N-Methyl-N-(2-(4-phenylthiazolyl) )amino]ethanol 24
[0180] The title compound was prepared as an oil from
2-chloro-4-phenylthiazole (13.5 g) and 2-methylaminoethanol (40 ml)
by an analogous procedure to that described in Preparation 7.
[0181] .sup.1H NMR .delta. (CDCl.sub.3)
[0182] 3.15 (3H, s); 3.6-4.0 (4H, m); 4.6 (1H, broad s, exchanges
with D.sub.20); 6.7 (1H, s); 7.2-7.9 (5H, complex).
[0183] Preparation 10
[0184] 2-[N-Methyl-N-(2-(4-phenyl-5-methylthiazolyl))amino]ethanol
25
[0185] The title compound was prepared as an oil from
2-chloro-4-phenyl-5-methylthiazole (18.9 g) and
2-methylaminoethanol (50 ml) by an analogous procedure to that
described in Preparation 7. .sup.1H NMR .delta. (CDCl.sub.3)
[0186] 2.38 (3H, s); 3.0 (3H, s); 3.45-3.85 (4H, m); 5.1 (1H, broad
s, exchanges with D.sub.2O); 7.1-7.7 (5H, complex).
[0187] Preparation 11
[0188] 2-[N-Methyl-N-(2-(4-methyl-5-phenylthiazolyl))amino]-ethanol
26
[0189] The title compound was prepared as an oil from
2-chloro-4-methyl-5-phenylthiazole (14.8 g) and
2-methylaminoethanol (40 ml) by an analogous procedure to that
described in Preparation 7.
[0190] .sup.1H NMR .delta. (CDCl.sub.3)
[0191] 2.35 (3H, s); 3.1 (3H, s); 3.5-4.0 (4H, m); 5.1 (1H, broad
s, exchanges with D.sub.2O); 7.1-7.5 (5H, complex).
[0192] Preparation 12
[0193] 2-[N-Methyl-N-(2-(4-methylthiazolyl))amino]ethanol 27
[0194] The title compound was prepared, by an analogous procedure
to that described in Preparation 7, and was used in the next stage
without further purification.
[0195] .sup.1H NMR .delta. (CDCl.sub.3)
[0196] 2.25 (3H, s); 3.1 (3H, s); 3.55-3.95 (4H, m); 4.9 (1H, broad
s, exchanges with D.sub.2O); 6.1 (1H, 3).
[0197] Preparation 13
[0198] 2-[N-Methyl-N-[2-(5-henyloxazolyl)]amino]ethanol 28
[0199] A solution of 2-chloro-5-phenyloxazole (8.3 g) and
2-methylaminoethanol (30 ml) was stirred at 50.degree. C. for 10
minutes. After cooling the oil was added to water (250 ml) and
extracted with ethyl acetate (2.times.150 ml). The organic extracts
were washed with brine (2.times.100 ml), dried (MgSO.sub.4),
filtered and evaporated to dryness to leave the title compound
(m.p. 73.degree.-75.degree. C.).
[0200] .sup.1H NMR .delta. (CDCl.sub.3)
[0201] 3.2 (3H, S); 3.6 (2H, t); 3.85 (2H, t); 3.9 (1H, broad s,
exchanges with D.sub.2O); 7.0 (1H, s); 7.2-7.55 (5H, complex).
[0202] Preparation 14
[0203] 4-[2-(N-Methyl-N-(2-(4,5-dimethylthiazolyl)amino)
ethoxy)]benzaldehyde 29
[0204] The title compound was prepared from
2-[N-methyl-N-(2-(4,5-dimethyl- thiazolyl))amino]ethanol (13.2 g)
and 4-fluorobenzaldehyde (23.1 g) by an analogous procedure to that
described in Preparation 5.
[0205] .sup.1H NMR .delta. (CDCl.sub.3)
[0206] 2.15 (3H, s); 2.2 (3H, s); 3.18 (3H, s); 3.8 (2H, t); 4.3
(2H, t); 7.0 (2H, d); 7.8 (2H, d); 10.0 (1H, s).
[0207] Preparation 15
[0208] 4-[2-(N-Methyl-N-(2-thiazolyl)amino)ethoxy]benzaldehyde
30
[0209] The title compound was prepared from
2-[N-methyl-N-(2-thiazolyl)ami- no]ethanol (10.7 g) and
4-fluorobenzaldehyde (15.9 g) by an analogous procedure to that
described in Preparation 5.
[0210] .sup.1H NMR .delta. (CDCl.sub.3)
[0211] 3.15 (3H, s); 3.9 (2H, t); 4.4 (2H, t); 6.5 (1H, d); 7.0
(2H, d); 7.15 (1H, d); 7.8 (2H, d); 9.9 (1H, s).
[0212] Preparation 16
[0213] 4-[2-(N-Methyl-N-(2-(4-phenylthiazolyl)amino)ethoxy)
benzaldehyde 31
[0214] The title compound was prepared from
2-[N-methyl-N-(2-(4-phenylthia- zolyl))amino]ethanol (16.1 g) and
4-fluorobenzaldehyde (17.4 g) by an analogous procedure to that
described in Preparation 5.
[0215] .sup.1H NMR .delta. (CDCl.sub.3)
[0216] 3.2 (3H, s); 3.95 (2H, t); 4.3 (2H, t); 6.7 (1H, s);
6.95-7.9 (9H, complex); 9.9 (1H, s).
[0217] Preparation 17
[0218] 4-[2-(N-Methyl-N-(2-(4-phenyl-5-methylthiazolyl)amino)
ethoxy)]benzaldehyde 32
[0219] The title compound was prepared from
2-[N-methyl-N-(2-(4-phenyl-5-m- ethylthiazolyl))amino]ethanol (13
g) and 4-fluorobenzaldehyde (9.8 g) by a similar procedure to that
described in Preparation 5.
[0220] .sup.1H NMR .delta. (CDCl.sub.3)
[0221] 2.35 (3H, s); 3.1 (3H, S); 3.8 (2H, t); 4.2 (2H, t);
6.85-7.8 (9H, complex); 9.85 (1H, S).
[0222] Preparation 18
[0223] 4-[2-(N-Methyl-N-(2-(4-methyl-5-phenyl-thiazolyl)amino)
ethoxy)]benzaldehyde 33
[0224] The title compound was prepared from
2-[N-methyl-N-(2-(4-methyl-5-p- henylthiazolyl))amino]ethanol (13
g) and 4-fluorobenzaldehyde (13 g) by an analogous procedure to
that described in Preparation 5.
[0225] .sup.1H NMR .delta. (CDCl.sub.3)
[0226] 2.36 (3H, s); 3.2 (3H, s); 3.9 (2H, t); 4.35 (2H, t); 7.05
(2H, d); 7.2-7.5 (5H, complex); 7.85 (2H, d); 9.95 (1H, s).
[0227] Preparation 19
[0228]
4-[2-(N-Methyl-N-(2-(4-methylthiazolyl))amino)ethoxy]benzaldehyde
34
[0229] The title compound was prepared from
2-[N-methyl-N-(2-(4-methylthia- zolyl))amino]ethanol (12 g) and
4-fluorobenzaldehyde (14.3 g) by an analogous procedure to that
described in Preparation 5.
[0230] .sup.1H NMR 4 (CDCl.sub.3)
[0231] 2.25 (3H, s); 3.2 (3H, s); 3.9(2H, t); 4.3 (2H, t); 6.1 (1H,
s); 7.05 (2H, d); 7.85 (2H, d); 9.95 (1H, s).
[0232] Preparation 20
[0233]
4-[2-(N-Methyl-N-[2-(5-phenyloxazolyl)]amino)ethoxy]benzaldehyde
35
[0234] The title compound was prepared from
2-[N-methyl-N-(2-(5-phenyloxaz- olyl))amino]ethanol (9.3 g) and
4-fluorobenzaldehyde (7.9 g) by an analogous procedure to that
described in Preparation 5.
[0235] .sup.1H NMR .delta. (CDCl.sub.3)
[0236] 3.25 (3H, s); 3.85 (2H, t); 4.3 (2H, t); 6.95-7.6 (8H,
complex); 7.8 (2H, d); 9.9 (1H, s).
[0237] Preparation 21
[0238] 2-[N-Methyl-N-[2-(4,5-dimethyloxazolyl)]amino]ethanol.
36
[0239] A solution of 2-chloro-4,5-dimethyloxazole (5 g) and
2-methylaminoethanol (15 ml) was stirred at 120.degree. C. for 40
minutes. After cooling the oil was added to water (200 ml) and
extracted with dichloromethane (3.times.200 ml). The organic
extracts were washed with brine (2.times.100 ml), dried
(MgSO.sub.4), filtered and evaporated to dryness to leave the title
compound as a waxy solid, which was used in Preparation 22 without
further purification.
[0240] .sup.1H NMR .delta. (CDCl.sub.3)
[0241] 1.95 (3H, s); 2.10 (3H, s); 3.05 (3H, s); 3.5 (2H, t); 3.8
(2H, t); 4.4 (1H, broad s, exchanges with D.sub.2O).
[0242] Preparation 22
[0243] 4-[2-(N-Methyl-N-[2-(4,5-dimethyloxazolyl)]amino)
ethoxy]benzaldehyde 37
[0244] To a stirred solution of
2-[N-methyl-N-[2-(4,5-dimethyloxazolyl)ami- no]ethanol (2.7 g) in
DMF (60 ml), under an atmosphere of nitrogen, was added portionwise
sodium hydride (0.7 g; 60% dispersion in oil). After the vigorous
reaction had subsided, 4-fluorobenzaldehyde (2.9 g) was added and
the reaction mixture was heated to 80.degree. C. for 16 hours.
After cooling, the mixture was added to water (400 ml). The aqueous
solution was extracted with diethyl ether (3.times.250 ml). The
organic extracts were washed with brine (2.times.100 ml), dried
(MgSO.sub.4), filtered and evaporated to dryness. The title
compound was obtained as an oil following chromatography of the
residue on silica-gel in 1% methanol in dichloromethane.
[0245] .sup.1H NMR .delta. (CDCl.sub.3)
[0246] 1.95 (3H, s); 2.15 (3H, s); 3.15 (3H, s); 3.8 (2H, t); 4.25
(2H, t); 7.0 (2H, d); 7.9 (2H, d); 10.0 (1H, s).
[0247] Preparation 23
[0248] 2-(N-(2-Benzoxazolyl)-N-methylamino)ethanol
4-toluenesulphonyl ester 38
[0249] 4-Toluenesulphonyl chloride (19.0 g) was added portionwise
to a solution of N-(2-benzoxazolyl)-N-methylaminoethanol (19.2 g)
in dry pyridine (100 ml) at room temperature. The mixture was
stirred at room temperature for 3 hours, added to water (500 ml)
and extracted with dichloromethane (3.times.250 ml). The combined
extracts were washed with 2M hydrochloric acid (3.times.250 ml),
saturated sodium bicarbonate solution (250 ml) and brine (250 ml),
dried (MgSO.sub.4), filtered and evaporated. The title compound was
obtained pure following crystallisation from ethanol (m.p.
119.degree.-121.degree. C.).
[0250] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0251] 2.25 (3H, s); 3.05 (3H, s); 3.75 (2H, t); 4.35 (2H, t);
7.0-7.4 (6H, complex); 7.70 (2H, d).
[0252] Preparation 24
[0253] 2-(N-(2-Benzoxazolyl)-N-methylamino)ethanol methanesulphonyl
ester 39
[0254] The title compound (m.p. 97.degree.-8.degree. C.) was
prepared from N-(2-benzoxazolyl)-N-methylaminoethanol (19.2 g) and
methanesulphonyl chloride (11.5 g) by a similar procedure to that
used in Preparation 23.
[0255] .sup.1H NMR .delta. (CDCl.sub.3)
[0256] 2.90 (3H, S); 3.25 (3H, s); 3.7 (2H, t); 4.5 (2H, t);
6.90-7.4 (4H, complex).
[0257] Preparation 25
[0258] 4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]-benzaldehyde
40
[0259] To a solution of 4-hydroxybenzaldehyde (7.32 g) in dry
dimethylformamide (100 ml) was added portionwise sodium hydride
(60%, 2.4 g) with stirring at room temperature under nitrogen. When
gas evolution ceased a solution of
2-(N-methyl-N-(2-benzoxazolyl)amino)ethanol 4-toluenesulphonyl
ester (17.3 g) in dry dimethylformamide was added dropwise. The
mixture was heated to 80.degree. C. and stirred at this temperature
overnight. After cooling, the solution was poured into iced water
(1 liter), extracted with ethyl acetate (3.times.500 ml), and the
combined extracts were washed with sodium hydroxide solution (2M;
500 ml) and brine (500 ml), dried (MgSO.sub.4), filtered and
evaporated. The title compound (m.p. 96.degree.-98.degree. C.) was
obtained pure after crystallisation from ethanol.
[0260] .sup.1H H NMR .delta. (DMSO-d.sub.6)
[0261] 3.25 (3H, s); 3.95 (2H, t); 4.40 (2H, t); 6.90-7.40 (6H,
complex); 7.85 (2H, d); 9.90 (1H, s).
[0262] Preparation 26
[0263] 4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]benzaldehyde
41
[0264] The title compound was prepared from 4-hydroxy benzaldehyde
(1.22 g) and 2-(N-methyl-N-(2-benzoxazolyl) -amino)ethanol
methanesulphonyl ester (2.7 g) in a similar manner to that
described in Preparation 25.
[0265] Preparation 27
[0266] 2-(2-Pyrimidinylamino)ethanol 42
[0267] 2-Chloropyrimidine (5 g) and ethanolamine (l5 ml) were
stirred for 2 hours at 140.degree. C. After cooling, the mixture
was added to water (200 ml) and continuously extracted with ethyl
acetate (500 ml) for 16 hours. The organic extract was dried
(MgSO.sub.4), filtered and evaporated to dryness. The title
compound was obtained as a solid (m.p. 66.degree. C.), following
chromatography on silica-gel in 3% methanol in dichloromethane.
[0268] .sup.1H NMR .delta. (CDCl.sub.3)
[0269] 3.55 (2H, complex); 3.8 (2H, t); 4.3 (1H, broad s, exchanges
with D.sub.2O); 6.1 (1H, broad s, exchanges with D.sub.2O); 6.55
(1H, t); 8.3 (2H, d).
[0270] Preparation 28
[0271] 4-f2-(2-Pyrimidinylamino)ethoxy]benzaldehyde 43
[0272] Sodium hydride (1.2 g; 60% dispersion in oil) was added
portionwise to a stirred solution of 2-(2-pyrimidinyl amino)ethanol
(4 g) in DMF (140 ml) under an atmosphere of nitrogen. After the
vigorous reaction had subsided 4-fluorobenzaldehyde (5.35 g) was
added and the solution heated to 80.degree. C. for 20 hours. After
cooling the mixture was added to water (500 ml) and extracted with
diethyl ether (3.times.300 ml). The organic extracts were washed
with brine (2.times.200 ml), dried (MgSO.sub.4), filtered and
evaporated to dryness. Chromatography of the residue on silica gel
in 2% methanol in dichloromethane afforded the title compound,
which was used in the next stage without further purification.
[0273] .sup.1H NMR .delta. (CDCl.sub.3)
[0274] 3.8 (2H, complex); 4.2 (2H, t); 5.7 (1H, broad s, exchanges
with D.sub.2O); 6.5 (1H, t); 7.0 (2H, d); 7.8 (2H, d); 8.3 (2H, d);
9.9 (1H, S).
[0275] Preparation 29
[0276] 2-(N-(2-Benzothiazolyl)-N-benzylamino)ethanol 44
[0277] 2-Chlorobenzothiazole (13 g) and 2-(benzylamino)ethanol (29
g) were heated together in a sealed vessel at 120.degree. C. for
20h.. After cooling, the reaction mixture was dissolved in ethyl
acetate (200 ml) and the solution was washed with saturated aqueous
sodium hydrogen carbonate (3.times.100 ml), water (3.times.100 ml)
and brine (100 ml), dried over anhydrous magnesium sulphate and
evaporated to give the title compound (m.p. 95.degree.-96.degree.
C.; dichloromethane/hexane).
[0278] .sup.1H NMR .delta. (CDCl.sub.3)
[0279] 3.8 (4H, m); 4.5 (1H, broad s, exchanges with D.sub.2O); 4.7
(2H, s); 6.9-7.7 (9H, complex).
[0280] Preparation 30
[0281] 4-(2-(N-(2-Benzothiazolyl)-N-benzylamino)ethoxy)benzaldehyde
45
[0282] The title compound was prepared from
2-(N-(2-benzothiazolyl)-N-benz- ylamino)ethanol (8.25 g) and
4-fluorobenzaldehyde (3.6 g) by an analogous procedure to that
described in Preparation 22.
[0283] .sup.1H NMR .delta. (CDCl.sub.3)
[0284] 4.0 (2h, t); 4.4 (2H, t); 4.9 (2H, s); 6.9-8.0 (13H,
complex); 10.0 (1H, s).
[0285] Preparation 31
[0286] 4-[3-(N-Methyl-N-(2-benzoxazolyl)-amino)propoxy]benzaldehyde
46
[0287] The title compound was prepared from
3-[(N-(2-benzoxazolyl)-N-methy- l)amino]propan-1-ol (7.5 g) and
4-fluorobenzaldehyde (6.78 g) by a similar procedure to that
described in Preparation 22.
[0288] .sup.1H NMR .delta. (CDCl.sub.3)
[0289] 2.0-2.4 (2H, complex); 3.2 (3H, S); 3.75 (2H, t); 4.2 (2H,
t); 6.8-7.5 (6H, complex); 7.8 (2H, d); 9.9 (1H, s).
[0290] Preparation 32
[0291] 3-[(N-(2-Benzoxazolyl)-N-methyl)amino)propan-1-ol 47
[0292] 2-Chlorobenzoxazole (15.36 g) in dry tetrahydrofuran (50 ml)
was added dropwise to a mixture of 3-N-methylaminopropan-1-ol (9.8
g) and triethylamine (20.2 g) in dry tetrahydrofuran (130 ml) with
stirring, at room temperature. After stirring at room temperature
overnight the solvent was evaporated. The residue was dissolved in
dichloromethane (150 ml), washed with water (3.times.100 ml), brine
(150 ml), dried (MgSO.sub.4), filtered and evaporated. The title
compound was obtained as an oil following chromatography on
silica-gel in 2.5-3% methanol in dichloromethane.
[0293] .sup.1H NMR .delta. (CDCl.sub.3)
[0294] 1.8-2.1 (2H, complex); 3.2 (3H, s); 3.5-3.85 (4H, complex);
4.3 (1H, broad s, exchanges with D.sub.2O); 6.8-7.5 (4H,
complex).
[0295] Preparation 33
[0296] 4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzaldehyde 48
[0297] The title compound was prepared from
2-(N-methyl-N-(2-pyridyl)amino- )ethanol (8.9 g) and
4-fluorobenzaldehyde by a similar procedure to that described in
Preparation 22.
[0298] .sup.1H NMR .delta. (CDCl.sub.3)
[0299] 3.2 (3H, s); 3.8 (2H, t); 4.2 (2H, t); 6.4 (2H, t); 6.9 (2H,
d); 7.3 (1H, complex); 7.75 (2H,d); 8.15 (1H,d); 9.9 (1H, s).
[0300] Preparation 34
[0301] 4-[N-(2-Benzoxazolyl)-N-methylamino]butan-1-ol 49
[0302] 2-Chlorobenzoxazole (15.35 g) was added dropwise over 10
minutes to a stirred solution of 4-(N-methylamino)butan-1-ol (10.3
g) and triethylamine (20.3 g) in dry tetrahydrofuran (150 ml). The
mixture was stirred at room temperature overnight, and then heated
at reflux for a further 2h. The resulting mixture was cooled and
the solvent was evaporated. The residue was dissolved in
dichloromethane (500 ml), washed with saturated sodium bicarbonate
solution (3.times.300 ml) and brine (500 ml), dried and evaporated
to afford the title compound as an oil.
[0303] .sup.1H NMR .delta. (CDCl.sub.3)
[0304] 1.5-2.0 (4H, complex); 3.1 (3H,s); 3.4-3.9 (5H, complex;
reduced to 4H after D.sub.20 exchange); 6.9-7.4 (4H, complex)
[0305] Preparation 35
[0306] 4-[(N-(2-Benzoxazolyl)-N-methyl)amino]butan-1-ol
methanesulphonyl ester 50
[0307] Methanesulphonyl chloride (3.15 g) was added dropwise to a
stirred, ice-cooled solution of
4-[N-(2-benzoxazolyl)-N-methylamino]butan-1-ol (5.5 g) and
4-dimethylaminopyridine (0.15 g) in pyridine (100 ml). The mixture
was allowed to warm to room temperature overnight, and then diluted
with water (500 ml), and extracted with dichloromethane
(3.times.200 ml). The combined extracts were washed with saturated
sodium bicarbonate solution (3.times.200 ml), and brine (200 ml),
then dried and the solvent evaporated to afford an oil. More of
this oil was obtained from the acidic aqueous layers by means of
adjusting the pH to 4.5 with solid potassium carbonate,
re-extracting with dichloromethane (3.times.200 ml), and drying and
evaporating these dichloromethane layers. The combined impure
product fractions were chromatographed on silica gel with 2%
methanol in dichloromethane as eluent to afford the title compound
as an oil.
[0308] .sup.1H NMR .delta. (CDCl.sub.3)
[0309] 1.80(4H,complex); 3.05(3H,s); 3.25(3H,s); 3.60(2H,complex);
4.30(2H,complex); 6.90-7.40(4H, complex).
[0310] Preparation 36
[0311] 4-[4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzaldehyde
51
[0312] The title compound was prepared from 4-hydroxybenzaldehyde
(1.71 g) and 4-[N-(2-benzoxazolyl)-N-methylamino]butan-1-ol
methanesulphonyl ester (3.80 g) by a similar procedure to that used
in Preparation 26.
[0313] .sup.1H NMR (CDCl.sub.3)
[0314] 1.70-1.95(4H, complex); 3.20(3H,s); 3.55(2H, complex);
4.00(2H, complex); 6.80-7.40(6H, complex) 7.75(2H,d);
9.90(1H,s)
[0315] Preparation 37
[0316] 2-[N-(2-Benzoxazolyl)amino]ethanol 52
[0317] A solution of 2-chlorobenzoxazole (12.78 g) in dry
tetrahydrofuran (50 ml) was added, over 10 minutes, to a stirred,
ice-cooled solution of ethanolamine (15.3 g) in dry tetrahydrofuran
(400 ml). The mixture was heated at reflux overnight, cooled, and
the solvent evaporated. The residue was partitioned between water
(500 ml) and dichloromethane (500 ml), and the resulting white
solid filtered off, washed with dichloromethane and dried in vacuo
to afford the title compound m.p. 162.degree.-4.degree. C.
[0318] .sup.1H NMR .delta. DMSO-d.sub.6
[0319] 3.3-3.8 (4H, complex); 5.0 (1H, br, exchanges with
D.sub.2O); 6.9-7.7 (4H, complex); 8.1 (1H, br, exchanges with
D.sub.2O).
[0320] Preparation 38
[0321] 2-[N-(2-Benzoxazolyl)amino]ethanol methanesulphonyl ester
53
[0322] Methanesulphonyl chloride (4.9 g) was added dropwise to a
stirred, ice-cooled solution of 2-[N-(2-benzoxazolyl)amino]ethanol
(6.23 g) and triethylamine (4.39 g) in dichloromethane (75 ml). The
resulting mixture was stirred at 0.degree. C. for 1.5h and then
diluted with dichloromethane (200 ml), washed with water
(2.times.200 ml), brine (200 ml) and dried. The dichloromethane
layer was evaporated and the residue chromatographed on silica gel
with 1.5% methanol in dichloromethane as eluent to give the title
compound, m.p. 96.degree.-9.degree. C.
[0323] .sup.1H NMR .delta. CDCl.sub.3
[0324] 3.0 (3H,s); 3.85 (2H,t); 4.5 (2H,t); 5.9 (1H,br, exchanges
with D.sub.2O); 7.0-7.5 (4H, complex).
[0325] Preparation 39
[0326] 4-[2-(N-(2-Benzoxazolyl)aminoethoxy]benzaldehyde 54
[0327] A mechanically stirred mixture of
2-[N-(2-benzoxazolyl)amino]ethano- l methanesulphonyl ester (5.77
g), 4-hydroxybenzaldehyde (2.81 g) and potassium carbonate (3.28 g)
was heated at 80.degree. C. overnight in dry DMF (250 ml). After
cooling, the reaction mixture was concentrated in vacuo, diluted
with water (500 ml) and extracted with ethyl acetate (3.times.300
ml). The combined ethyl acetate layers were washed with water
(2.times.1l), brine (1l), dried and evaporated. The resulting solid
was chromatographed on silica gel with 1.5% methanol in
dichloromethane as eluent to afford the title compound, m.p.
103.degree.-6.degree. C.
[0328] .sup.1H NMR .delta. CDCl.sub.3
[0329] 3.9 (2H,t); 4.3 (2H,t); 6.4(1H, br, exchanges with
D.sub.2O); 6.9-8.0 (8H, complex); 9.9 (1H,s).
[0330] Preparation 40
[0331] 2-[N-Isopropyl-N-(2-benzoxazolyl)amino]ethanol 55
[0332] 2-Chlorobenzoxazole (23.04 g) was added dropwise to an
ice-cooled solution of 2-(isopropylamino)ethanol (15.45 g) and
triethylamine (30.3 g) in tetrahydrofuran (500 ml). The mixture was
stirred at room temperature for 30 minutes, then heated at reflux
overnight before being cooled and evaporated. The residue was
dissolved in dichloromethane (800 ml) and washed with saturated
sodium bicarbonate solution (500 ml), water (3.times.1l) brine
(1l), dried (MgSO.sub.4), filtered and evaporated. The title
compound was obtained as an oil following chromatography on silica
gel using 1.5% methanol-dichloromethane as solvent.
[0333] .sup.1H NMR .delta. (CDCl.sub.3)
[0334] 1.25 (6H,d); 3.6 (2H,t); 3.9 (2H,t); 4.5 (1H,m); 4.55 (1H,
broad s, exchanges with D.sub.2O); 6.95 - 7.50 (4H, complex).
[0335] Preparation 41
[0336] 2-[N-Isopropyl-N-(2-benzoxazolyl)amino]ethanol
methanesulphonyl ester. 56
[0337] The title compound was prepared from 2-[N-isopropyl
-N-(2-benzoxazolyl)amino]ethanol and methanesulphonyl chloride by a
similar procedure to that described in Preparation 38.
[0338] .sup.1H NMR .delta. (CDCl.sub.3)
[0339] 1.35 (6H,d); 3.0 (3H,s); 3.8 (2H,t); 4.3-4.7 (3H, complex);
6.9-7.5 (4H, complex).
EXAMPLE 1
[0340]
5-(4-[2-(N-Methyl-N-(2-benzothiazolyl)amino)ethoxy]benzyl)-2,4-thia-
zolidinedione. 57
[0341]
5-(4-[2-(N-Methyl-N-(2-benzothiazolyl)amino)ethoxy]benzylidene)-2,4-
-thiazolidinedione (2 g) in dry 1,4-dioxan (70 ml) was reduced
under hydrogen in the presence of 10% palladium on charcoal (3 g)
at ambient temperature and atmospheric pressure until hydrogen
uptake ceased. The solution was filtered through diatomaceous
earth, the filter pad was washed exhaustively with dioxan and the
combined filtrates were evaporated to dryness under vacuum. The
title compound (m.p. 167.degree.-8.degree. C.) was obtained after
crystallisation from methanol.
[0342] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0343] 2.9-3.4 (2H, complex); 3.25 (3H, s); 3.9 (2H, complex); 4.25
(2H, complex); 4.8 (1H, complex); 6.8-7.75 (8H, complex); 12.0 (1H,
s, exchanges with D.sub.2O).
EXAMPLE 2
[0344]
5-(4-[2-(N-Methyl-N-(2-benzothiazolyl)amino)ethoxy]benzylidene)-2,4-
-thiazolidinedione. 58
[0345] A solution of 4-[2-(N-methyl-N-(2-benzothiazolyl)amino)
ethoxy]benzaldehyde (1.9 g) and 2,4-thiazolidinedione (0.8 g) in
toluene (100 ml) containing a catalytic quantity of piperidinium
acetate was boiled under reflux in a Dean and Stark apparatus for 2
hours. The mixture was cooled and filtered and the filtered solid
was dried to give the title compound (mp 219.degree. C.).
[0346] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0347] 3.2 (3H, s); 3.9 (2H, t); 4.35 (2H, t); 6.8-7.7 (10H,
complex).
EXAMPLE 3
[0348]
5-(4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazo-
lidinedione hemihydrate 59
[0349]
5-(4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]-benzylidene)-2,4--
thiazolidinedione (1.5 g) in dry 1,4-dioxan (80 ml) was reduced
under hydrogen in the presence of 10% palladium on charcoal (2 g)
at ambient temperature and atmospheric pressure until hydrogen
uptake ceased. The solution was filtered through diatomaceous
earth, the filter pad was washed exhaustively with dioxan and the
combined filtrates were evaporated to dryness under vacuum. The
title compound (mp 147.degree.-9.degree. C.) was obtained after
crystallisation from methanol.
[0350] .sup.1H NMR .delta. (DMSO-d.sub.6+D.sub.2O)
[0351] 3.1-3.5 (2H, complex); 3.3 (3H,s); 3.95 (2H, complex); 4.25
(2H, complex); 4.5 (1H, complex); 6.8-7.3 (8H, complex).
EXAMPLE 4
[0352]
5-(4-[2-(N-Methyl-N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,4-t-
hiazolidinedione 60
[0353] A solution of 4-12-(N-methyl-N-(2-benzoxazolyl)amino)
ethoxy]benzaldehyde (1.6 g) and 2,4-thiazolidinedione (0.63 g) in
toluene (100 ml) containing a catalytic quantity of piperidinium
acetate was boiled under reflux in a Dean and Stark apparatus for 2
hours. The mixture was cooled and filtered to give the title
compound (mp 227.degree.-9.degree. C.)
[0354] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0355] 3.20 (3H, s); 3.90 (2H, t); 4.30 (2H, t); 6.9-7.75 (10H,
complex).
EXAMPLE 5
[0356]
5-(4-[2-(N-Methyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazol-
idinedione 61
[0357] 5-(4-[2-(N-Methyl-N-(2-pyrimidinyl)amino)
ethoxy]benzylidene)-2,4-t- hiazolidinedione (2.4 g) in dry
1,4-dioxan (150 ml) was reduced under hydrogen in the presence of
10% palladium on charcoal (3 g) until hydrogen uptake ceased. The
solution was filtered through diatomaceous earth, the filter pad
was washed exhaustively with dioxan and the combined filtrates were
evaporated to dryness under vacuum. The title compound (mp
150.degree.-51.degree. C.) was obtained after crystallisation from
methanol.
[0358] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0359] 2.9-3.4 (2H, complex); 3.2 (3H, s); 3.9 (2H, complex); 4.2
(2H, complex); 4.9 (1H, complex); 6.6 (1H, t); 6.9 (2H, d); 7.2
(2H, d); 8.4 (2H, d); 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 6
[0360]
5-(4-[2-(N-Methyl-N-(2-pyrimidinyl)amino)ethoxy]benzylidene)-2,4-th-
iazolidinedione 62
[0361] A solution of 4-[2-(N-methyl-N-(2-pyrimidinyl)amino)
ethoxy]benzaldehyde (1.7 g) and 2,4-thiazolidinedione (0.7 g) in
toluene (100 ml) containing a catalytic quantity of piperidinium
acetate was boiled under reflux in a Dean and Stark apparatus for 2
hours. The mixture was cooled and filtered to give the title
compound (mp 189.degree.-90.degree. C.).
[0362] .sup.1H NMR .delta. (DMSO-d6+D.sub.2O)
[0363] 3.2 (3H, s); 3.7-4.4 (4H, complex); 6.6 (1H, t); 7.1 (2H,
d), 7.5 (2H, d); 7.7 (1H, s); 8.4 (2H, d).
EXAMPLE 7
[0364] 5-(4-(2-(N-Methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
ethoxy]benzyl)-2,4-thiazolidinedione 63
[0365] 5-(4-[2-(N-Methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
ethoxy]benzylidene-2,4-thiazolidinedione (1.6 g) was dissolved in a
mixture of methanol (50 ml) and dioxan (50 ml). Magnesium turnings
(1.5 g) were added and the solution stirred until no more
effervescence was observed. The mixture was added to water (300
ml), acidified (2M HCl) to form a solution, neutralised (saturated
NaHCO.sub.3 solution), filtered and dried. The solid was dissolved
in dioxan (100 ml), adsorbed onto silica (20 g) and the title
compound (m.p. 177.degree. C.; MeOH) obtained following
chromatography on silica-gel in 5% dioxan in dichloromethane.
[0366] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0367] 2.05 (3H, s); 2.15 (3H, s); 3.0 (3H, s); 3.0-3.4 (2H,
complex); 3.8 (2H, t); 4.2 (2H, t); 4.85 (1H, complex); 6.9 (2H,
d); 7.1 (2H, d); 12.0 (1H, broad s exchanges with D.sub.2O).
EXAMPLE 8
[0368] 5-(4-[2-(N-Methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
ethoxy]benzylidene)-2,4-thiazolidinedione 64
[0369] The title compound (m.p. 175.degree. C.) was prepared by a
similar procedure to that described in Example 4.
[0370] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0371] 2.0 (3H, s); 2.1 (3H, s); 3.0 (3H, s); 3.7 (2H, t); 4.25
(2H, t); 7.1 (2H, d); 7.55 (2H, d); 7.75 (1H, s); 12.0 (1H, broad
s, exchanges with D.sub.2O).
EXAMPLE 9
[0372] 5-(4-[2-(N-Methyl-N-(2-thiazolyl)aminoethoxy]ben
-2,4-thiazolidinedione 65
[0373] The title compound (m.p. 186.degree. C.; MeOH) was prepared
by an analogous procedure to that described in Example 7.
[0374] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0375] 3.0-3.4 (2H, complex); 3.1 (3H, s); 3.8 (2H, t); 4.2 (2H,
t); 4.85 (1H, complex); 6.7-7.3 (6H, complex); 12.0 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 10
[0376]
5-(4-[2-(N-Methyl-N-(2-thiazolyl)amino)ethoxy]benzylidene)-2,4-thia-
zolidinedione 66
[0377] The title compound (m.p. 212.degree. C.) was prepared by a
similar procedure to that described in Example 4.
[0378] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0379] 3.1 (3H, S); 3.85 (2H, t); 4.3(2H, t); 6.75 (1H, d); 7.1-7.3
(3H, complex); 7.6 (2H, d); 7.75 (1H, s); 12.0 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 11
[0380] 5-[4-(2-(N-Methyl-N-(2-(4-phenylthiazolyl))amino)
ethoxy)benzyl]-2,4-thiazolidinedione 67
[0381] The title compound was obtained as a foam (m.p.
62.degree.-65.degree. C.) from
5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl)-
)amino)ethoxy)benzylidene]-2,4-thiazolidinedione (1.6 g) by a
similar procedure to that described in Example 7.
[0382] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0383] 3.15 (3H, s); 3.0-3.4 (2H, complex); 3.9 (2H, t); 4.25 (2H,
t); 4.85 (1H complex); 6.9 (2H, d); 7.1-7.45 (6H, complex); 7.85
(2H, d); 12.0 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 12
[0384] 5-(4-[2-(N-Methyl-N-(2-(4-phenylthiazolyl))amino)
ethoxy]benzylidene)-2,4-thiazolidinedione 68
[0385] The title compound (m.p. 134.degree. C.) was prepared from
4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)ethoxy] benzaldehyde
by a similar procedure to that described in Example 4.
[0386] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0387] 3.2 (3H, 3); 3.9 (2H, t); 4.35 (2H, t); 7.1-7.95 (11H,
complex); 12.0 (1H broad s, exchanges with D.sub.2O).
EXAMPLE 13
[0388]
5-(4-[2-(N-Methyl-N-f2-(4-phenyl-5-methylthiazolyl)]amino)ethoxy]be-
nzyl)-2,4-thiazolidinedione 69
[0389] The title compound, obtained as a foam (m.p.
60.degree.-62.degree. C.), was prepared by an analogous procedure
to that described in Example 7.
[0390] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0391] 2.35 (3H, s); 3.1 (3H, s); 3.0-3.4 (2H, complex); 3.8 (2H,
t); 4.2 (2H, t); 4.85 (1H, complex); 6.9 (2H, d); 7.2 (2H, d);
7.25-7.5 (3H, complex); 7.65 (2H, d); 12.0 (1H, broad s, exchanges
with D.sub.2O).
EXAMPLE 14
[0392] 5-(4-[2-(N-Methyl-N-[2-(4-phenyl-5-methylthiazolyl)l
amino)ethoxy]benzylidene)-2,4-thiazolidinedione 70
[0393] The title compound was prepared from
4-[2-(N-methyl-N-[2-(4-phenyl--
5-methylthiazolyl)]amino)ethoxy]benzaldehyde by a similar procedure
to that described in Example 4, and was used in Example 13 without
further purification.
[0394] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0395] 2.4 (3H, s); 3.1 (3H, S); 3.8 (2H, t); 4.35 (2H, t);
7.1-7.75 (10H, complex); 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 15
[0396]
5-(4-[2-(N-Methyl-N-[2-(4-methyl-5-phenylthiazolyl)]amino)ethoxy]be-
nzyl)-2,4-thiazolidinedione 71
[0397] The title compound (m.p. 174.degree. C.; MeOH) was prepared
from
5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]-amino)ethoxy]benzyli-
dene)2,4-thiazolidinedione by an analogous procedure to that
described in Example 7.
[0398] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0399] 2.3 (3H, s); 3.0-3.4 (2H, complex); 3.15 (3H, s); 3.85 (2H,
t); 4.25 (2H, t); 4.85 (1H, complex); 6.95 (2H, d); 7.2 (2H, d);
7.45 (5H, complex); 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 16
[0400] 5-(4-[2-(N-Methyl-N-[2-(4-methyl-5-phenylthiazolyl)l
amino)ethoxy]benzylidene)-2,4-thiazolidinedione 72
[0401] The title compound was prepared from
4-[2-(N-methyl-N-[2-(4-methyl--
5-phenylthiazolyl)]amino)ethoxy]benzaldehyde by a similar procedure
to that described in Example 4, and was used in Example 15 without
further purification.
[0402] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0403] 2.3 (3H, s); 3.1 (3H, S); 3.85 (2H, t); 4.35 (2H, t);
7.15-7.75 (1OH, complex); 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 17
[0404]
5-(4-[2-(N-Methyl-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzyl)-2,4-
-thiazolidinedione 73
[0405] The title compound, was prepared from 5-(4-(2-(N-methyl
-N-[2-(4-methylthiazolyl)]amino)ethoxy]benzylidene)-2,4-thiazolidinedione
as a foam (m.p. 121.degree. C.), by a similar procedure to that
described in Example 7.
[0406] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0407] 2.1 (3H, s); 3.0-3.4 (2H, complex); 3.1 (3H, s); 3.75 (2H,
t); 4.15 (2H, t); 4.85 (1H, complex); 6.3 (1H, s); 6.9 (2H, d); 7.2
(2H, d); 12.0 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 18
[0408] 5-(4-[2-(N-Methyl-N-f2-(4-methylthiazolyl)]amino)
ethoxy]benzylidene)-2,4-thiazolidinedione 74
[0409] The title compound was prepared from
5-(4-[2-(N-methyl-N-[2-(4-meth-
ylthiazolyl)]amino)ethoxy]benzaldehyde by a similar procedure to
that described in Example 4, and was used in the Example 17 without
further purification.
[0410] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0411] 2.1 (3H, s); 3.1 (3H, s); 3.85 (2H, d); 4.3 (2H, d); 6.3
(1H, s); 7.15 (2H, d); 7.6 (2H, d); 7.75 (1H, s); 12.0 (1H, broad
s, exchanges with D.sub.2O).
EXAMPLE 19
[0412] 5-[4-(2-(N-Methyl-N-[2-(5-phenyloxazolyl)]amino
ethoxy)benzyl]-2,4-thiazolidinedione 75
[0413] The title compound (m.p. 200.degree. C., MeOH)) was prepared
from 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino
ethoxy)benzylidene]-2,4-t- hiazolidinedione by a similar procedure
to that described in Example 7.
[0414] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0415] 3.0-3.4 (2H, complex); 3.15 (3H, s); 3.8 (2H, t); 4.2 (2H,
t); 4.85 (1H, complex); 6.9 (2H, d); 7.1-7.4 (6H, complex); 7.5
(2H, d); 12.0 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 20
[0416] 5-(4-[2-(N-Methyl-N-[2-(5-Phenyloxazolyl)]amino)
ethoxy]benzylidene)-2,4-thiazolidinedione 76
[0417] The title compound (m.p. 191.degree. C.) was prepared from
4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino) ethoxy]benzaldehyde
by an analogous procedure to that described in Example 4.
[0418] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0419] 3.2 (3H, s); 3.8 (2H, t); 4.35 (2H, t); 7.1-7.7 10H,
complex); 7.8 (1H, s5); 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 21
[0420] 5-(4-[2-(N-Methyl-N-[2-(4,5-dimethyloxazolyl)]amino)
ethoxy]benzyl)-2,4-thiazolidinedione 77
[0421] 5-(4-[2-(
N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)-ethoxy]benzyl-
idene)-2,4-thiazolidinedione (1.2 g) in dry 1,4-dioxan (100 ml)
was-reduced under hydrogen in the presence of 10% Palladium on
charcoal (2.5 g) until hydrogen uptake ceased. The solution was
filtered through diatomaceous earth, the filter pad was washed
exhaustively with dioxan and the combined filtrates evaporated to
dryness under vacuum. The title compound was obtained as a foam
(m.p. 53.degree.-54.degree. C.) following chromatography on
silica-gel in 1% methanol in dichloromethane.
[0422] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0423] 1.85 (3H, s); 2.05 (3H, s); 3.0 (3H, s); 16.6; 3.0-3.4 (2H,
complex); 3.65 (2H, t); 4.1 (2H, t); 4.85 (1H, complex); 6.85 (2H,
d); 7.15 (2H, d); 18 12.0 (1H, broad s, exchanges with
D.sub.2O).
EXAMPLE 22
[0424]
5-(4-[2-(N-Methyl-N-[2-(4,5-dimethyloxazolyl)]amino)-ethoxy]benzyli-
dene)-2,4-thiazolidinedione 78
[0425] The title compound (softens at 149.degree. C.) was prepared
by a similar procedure to that described in Example 4.
[0426] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0427] 1.85 (3H, s); 2.05 (3H, s); 3.0 (3H, s); 3.7 (2H, t); 4.25
(2H, t); 7.1 (2H, d); 7.5 (2H, d); 7.75 (1H, s); 12.0 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 23
[0428]
5-[4-(2-(2-Pyrimidinylamino)ethoxy)benzyl]-2,4-thiazolidinedione
79
[0429] A mixture of 5-(4-(2-(2-pyrimidinylamino)ethoxy)
benzylidene]-2,4-thiazolidinedione (3 g) and 10% palladium on
charcoal (9 g) in DMF (70 ml) was stirred under a pressure of 200
psi of hydrogen until hydrogen uptake ceased. The mixture was
filtered through diatomaceous earth, and the filter pad washed
exhaustively with DMF. The combined filtrates were evaporated to
dryness and the title compound (m.p. 173.degree. C.) obtained
following recrystallization from methanol.
[0430] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0431] 3.0-3.4 (2H, complex); 3.65 (2H, complex); 4.1 (2H, t); 4.85
(1H, complex); 6.6 (1H, t); 6.85 (2H, d); 7.15 (2H, d); 7.25 (1H,
t, exchanges with D.sub.2O); 8.3 (2H, d); 12.0 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 24
[0432]
5-[4-(2-(2-Pyrimidinylamino)ethoxy)benzylidene]-2,4-thiazolidinedio-
ne 80
[0433] The title compound (m.p. 234.degree. C.) was obtained from
4-(2-(2-pyrimidinylamino)ethoxy]benzaldehyde and
2,4-thiazolidindione, by an analogous procedure to that described
in Example 6.
[0434] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0435] 3.65 (2H, complex); 4.2 (2H,t); 6.6 (1H, t); 7.0-7.6 (5H,
complex, one pro ton changes with D.sub.2O); 7.7 (1H, s); 8.3 (2H,
d); 12.0 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 25
[0436] 5-(4-[2-(N-Acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)
-2,4-thiazolidinedione 81
[0437] A stirred solution of 5-(4-(2-(2-pyrimidinylamino)
ethoxy)benzyl]-2,4-thiazolidinedione (800 mg) in acetic anhydride
(15 ml) and 1,4-dioxan (5 ml) was boiled under reflux for 3 hours.
After cooling, the mixture was added to water (300 ml), neutralized
(sodium bicarbonate) and extracted with dichloromethane
(3.times.200 ml). The organic extracts were washed with brine (100
ml), dried (MgSO.sub.4), filtered and evaporated to dryness.
Chromatography on silica-gel in dichloromethane of the residual oil
afforded the title compound (m.p. 137.degree. C.).
[0438] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0439] 2.3 (3H, s); 2.93.4 (2H, complex); 4.15 (2H,t); 4.35 (2H,
t); 4.85 (1H, complex); 6.7 (2H,d); 7.1 (2H, d); 7.35 (1H, t); 8.8
(214, d); 12.0 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 26
[0440] 5-(4-(2-(N-(2-Benzothiazolyl)-N-benzylamino)ethoxy)
benzylidene)-2,4-thiazolidinedione 82
[0441] 4-(2-(N-(2-Benzothiazolyl)-N-benzylamino)ethoxy)
benzaldehyde (3 g) and 2,4-thiazolidinedione (1 g) were dissolved
in toluene (200 ml) containing piperidine (0.2 ml) and benzoic acid
(0.2 g) and heated to reflux for 4h. in a Dean and Stark apparatus.
On cooling, the solution was concentrated under vacuum to 50% of
its volume and the title compound, which crystallised, was
collected by filtration and dried in vacuo (m.p.
185.degree.-188.degree. C.). It was used in Example 27 without
further purification.
[0442] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0443] 4.0 (2H, t); 4.4 (2H, t); 4.9 (2H, s); 7.1-7.9 (14H,
complex); 12-13 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 27
[0444] 5-(4-(2-(N-(2-Benzothiazolyl) -N-benzylamino) ethoxy)
benzyl)-2,4-thiazolidinedione 83
[0445] 5-(4-(2-(N-(2-Benzothiazolyl)-N-benzylamino)ethoxy)
benzylidene)-2,4-thiazolidinedione (2.4 g) in dioxan (150 ml) was
hydrogenated in the presence of 10% palladium-charcoal (4.8 g) for
3h. at room temperature and atmospheric pressure. A further portion
of catalyst (2.4 g) was added and the hydrogenation continued for a
total of 20h. The mixture was filtered through diatomaceous earth
and the solvent was evaporated. The residue was chromatographed on
silica gel with 3% methanol-dichloromethane as eluant to afford the
title compound as a foam, which collapsed at 78.degree. C.
[0446] .sup.1H NMR .delta. (CDCl.sub.3)
[0447] 3.1 (1H, dd); 3.4 (1H, dd); 4.0 (2H, t); 4.25 (2H, t); 4.5
(1H, dd); 4.9 (2H, s); 6.8-7.6 (13H, m); 8.3 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 28
[0448]
5-(4-[3-(N-Methyl-N-(2-benzoxazolyl)amino)propoxy]benzyl)-2,4-thiaz-
olidinedione 84
[0449] The title compound (m.p. 171.degree.-3.degree. C.; ethanol)
was prepared from
5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)-propoxy]benzylid-
ene)-2-4-thiazolidinedione by a similar procedure to that described
in Example 1.
[0450] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0451] 2.0-2.35 (2H, complex); 2.9-3.6 (2H, complex); 3.2 (3H, s);
3.7 (2H, t); 4.2 (2H, t); 4.9 (1H, complex); 6.8-7.4 (8H, complex);
12-12.5 (1H, broad s, exchanges with D.sub.2O).
EXAMPLE 29
[0452]
5-(4-[3-(N-Methyl-N-(2-benzoxazolyl)amino)propoxyl-benzylidene)-2,4-
-thiazolidinedione 85
[0453] The title compound (m.p. 202.degree.-204.degree. C.) was
prepared from
4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzaldehyde (5.3 g)
and 2,4-thiazolidinedione (2.2 g) by a similar procedure to that
described in Example 4.
[0454] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0455] 2.0-2.35 (2H, complex); 3.15 (3H, s); 3.7 (2H, t); 4.2 (2H,
t); 7.0-7.7 (8H, complex); 7.8 (1H, s); 12.0 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 30
[0456]
5-(4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidin-
edione 86
[0457] The title compound (m.p. 153.degree.-5.degree. C.; MeOH) was
obtained from
5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzylidene)-2-
,4-thiazolidinedione by a similar procedure to that described in
Example 1.
[0458] .sup.1H NMR .delta. (DMSO-d.sub.6)
[0459] 2.9-3.4 (2H, complex); 3.1 (3H, s); 3.9 (2H, t); 4.1S (2H,
t); 4.8 (1H, complex); 6.5-6.85 (2H, complex); 6.8 (2H, d); 7.2
(2H, d); 7.5 (1H, complex); 8.1 (1H, d); 12.05 (1H, broad s,
exchanges with D.sub.2O).
EXAMPLE 31
[0460]
5-(4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazo-
lidinedione 87
[0461] The title compound (m.p. 177.degree.-9.degree. C.) was
obtained from 4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzaldehyde
(3.2 g) and 2,4-thiazolidinedione (1.1 g) by a similar procedure to
that described in Example 4.
[0462] .sup.1H NMR .delta. (DMSO-D.sub.2)
[0463] 3.1 (3H, s); 3.9 (2H, t); 4.2 (2H, t); 6.4-7.5 (7H,
complex); 7.7 (1H, s); 8.1 (1H, d)
EXAMPLE 32
[0464]
5-(4-f4-(N-Methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-t-
hiazolidinedione. 88
[0465] The title compound (m.p. 168.degree. C.) was prepared from
4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzaldehyde (3.5 g)
and 2,4-thiazolidinedione (1.4 g) by a similar procedure to that
described in Example 4.
[0466] .sup.1 NMR .delta. DMSO-d.sub.6
[0467] 1.70 (4H, complex); 3.10 (3H, s); 3.25 (1H, exchanges with
D.sub.2O); 3.50 (2H, complex); 4.05 (2H, complex); 6.90-7.60 (8H,
complex); 7.70 (1H, s).
EXAMPLE 33
[0468]
5-(4-[4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]-benzyl)-2,4-thiaz-
olidinedione 89
[0469] The title compound (m.p. 112.degree. C., ethanol-hexane) was
prepared from
5-(4-[4-(N-methyl-N-(2-benzoxazolyl)-amino)butoxy]benzylide-
ne)-2,4-thiazolidinedione by a similar procedure to that described
in Example 1.
[0470] .sup.1H NMR .delta. CDCl.sub.3
[0471] 1.85 (4H, complex); 3.10 (1H, complex); 3.15 (3H,s); 3.40
(1H,dd); 3.60 (2H,t); 4.00 (2H,t); 4.50 (1H,dd); 6.80-7.40 (8H,
complex); 9.30 (1H, br, exchanges with D.sub.2O).
EXAMPLE 34
[0472]
5-(4-[2-(N-(2-Benzoxazolyl)aminoethoxy]benzylidene)-2,4-thiazolidin-
edione 90
[0473] The title compound (m.p. 242.degree.-5.degree. C.) was
prepared from 4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzaldehyde
(5.18 g) and 2,4-thiazolidinedione (2.36 g) by a similar procedure
to that described in Example 4.
[0474] .sup.1H NMR .delta. DMSO-d.sub.6
[0475] 3.80 (2H,t); 4.35 (2H,t); 7.00-8.00 (9H, complex); 8.20 (1H,
br, exchanges with D.sub.2O); 13.5 (1H, br, exchanges with
D.sub.2O).
EXAMPLE 35
[0476] 5-(4-[2-(N-(2-Benzoxazolyl)amino)ethoxy]benzyl)-2,
4-thiazolidinedione 91
[0477] The title compound (m.p. 202.degree.-3.degree. C.;
dichloromethane) was prepared from
5-(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-2,-
4-thiazolidinedione (6.1 g) by a similar procedure to that
described in Example 1.
[0478] .sup.1H NMR .delta. DMSO-d.sub.6
[0479] 3.10 (1H,dd); 3.30 (1H,dd) 3.70 (2H, complex); 4.15 (2H,t);
4.85 (1H,dd); 6.80-7.50 (8H, complex); 8.15 (1H, complex; exchanges
with D.sub.2O); 12.00 (1H, br, exchanges with D.sub.2O).
EXAMPLE 36
[0480]
5-(4-[2-(N-Isopropyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thi-
azolidinedione. 92
[0481] Sodium hydride (60% dispersion in mineral oil, 0.93 g) was
added portionwise to a stirred solution of
5-(4-hydroxybenzyl)-2,4-thiazolidine- dione (2.45 g in dry DMF (50
ml)) at room temperature under a nitrogen atmosphere. The mixture
was stirred for 1 hour prior to the addition of a solution of
2-(N-isopropyl-N-(2-benzoxazolyl)amino]ethanol methanesulphonyl
ester (3.3 g) in dry DMF (60 ml). After stirring at room
temperature for a further hour, the mixture was heated at
80.degree. C. for 21 hours, then cooled, diluted with water (1l)
and acidified to pH 6.5 with hydrochloric acid. The resulting
suspension was extracted with ethyl acetate (2.times.500 ml), and
the combined ethyl acetate layers washed with water (3.times.1l),
brine (1l), dried (MgSO.sub.4) and evaporated. The residual oil was
chromatographed on silica gel with 1.5% methanol-dichloromethane as
solvent to afford the title compound as a foam (m.p. 66.degree.
C.).
[0482] .sup.1H NMR .delta. (CDCl.sub.3)
[0483] 1.35 (6H,d); 3.1 (1H, dd); 3.4 (1H, dd); 3.8 (2H,t); 4.15
(2H, complex); 4.35-4.65 (2H, complex); 6.85-7.4 (8H, complex); and
9.15 (1H, broad s,; exchanges with D.sub.2O).
[0484] DEMONSTRATION OF EFFICACY OF COMPOUNDS
[0485] Obese Mice, Oral Glucose Tolerance Test.
[0486] C57bl/6 obese (ob/ob) mice were fed on powdered oxoid diet.
After at least one week, the mice continued on a powdered oxoid
diet or were fed powdered oxoid diet containing the test compound.
After 8 days on the supplemented diet all of the mice were fasted
for 5 hours prior to receiving an oral load of glucose (3 g/kg).
Blood samples for glucose analysis were taken 0, 45, 90 and 135
minutes after glucose administration and the results appear below
as the percentage reduction in area under the blood glucose curve
where test compound treated groups are compared with the control
groups. 7 mice were used for each treatment.
1 LEVEL IN DIET % REDUCTION IN AREA (.mu.mol kg.sup.-1 of UNDER
BLOOD GLUCOSE EXAMPLE NO: DIET) CURVE 1 100 51 2 300 30 3 10 39 4
300 30 5 100 40 7 50 47 9 100 58 11 100 34 13 100 37 15 100 39 17
100 34 19 30 22 21 30 33 24 30 15 25 30 19 27 300 56 29 300 32 33
300 25 35 100 44 36 100 20
[0487] Anti-Hypertensive Activity
[0488] Eight month old female, spontaneously hypertensive rats were
given test compound once each day for 15 days. Prior to the
experiment and on days 8 and 15, the rats were fasted overnight
from 5.00 pm and blood pressure was recorded the following morning,
immediately prior to dosing and again 2h later. Food was returned
after the 2h blood pressure reading.
[0489] The results below were obtained using the compound of
Example 3 as the test compound.
2 Blood pressure (mm Hg) Treatment Group Time 0 hours 2 hours
Control Day 0 210 + 13 -- Test Compound (30 .mu.mole/kg) Day 0 210
.+-. 13 -- Test Compound (10 .mu.mole/kg) Day 0 210 .+-. 13 --
Control Day 8 196 .+-. 11 195 .+-. 12 Test Compound (30
.mu.mole/kg) Day 8 181 .+-. 11* 174 .+-. 15** Test Compound (10
.mu.mole/kg) Day 8 191 .+-. 6 185 .+-. 12 Control Day 15 208 .+-.
12 208 .+-. 9 Test Compound (30 .mu.mole/kg) Day 15 178 .+-. 18**
170 .+-. 13*** Test Compound (10 .mu.mole/kg) Day 15 198 .+-. 17
185 .+-. 5***
[0490] Significance of difference from control value at same
timepoint:
[0491] *p<0.05; **p<0.01; ***p<0.001.
[0492] Toxicology
[0493] No toxicological effects were indicated for any of the
compounds of the invention in any of the abovementioned tests.
* * * * *